Anticoagulant (blood thinner) such as apixaban, a factor Xa inhibitor, is being tested. In the AVERROES trial, 5599 atrila fibrillation (irregular heart rhythms of the smaller atrial chamber) patients in whom warfarin was felt to be unsuitable were randomly assigned to either apixaban or aspirin. The study was stopped prematurely because of a clear benefit in favor of apixaban (lower rate of paralysis or systemic embolism).
( N Engl J Med 2011; 364:806)
No comments:
Post a Comment